IDYA: רווח נקי למניה ב-12 החודשים האחרונים ideayabio.com
The financial stability of IDEAYA Biosciences (IDYA) is constrained by a lack of recurring revenue and a dependence on external capital. The trailing 12-month EPS, with a metric value of -4.49, illustrates this volatility. These risks are mitigated by a staff of leading scientists with high option-based incentives and strategic alliances with pharma behemoths, which provide the company with the resources necessary to develop targeted therapy.
%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%90%D7%A8%D7%91%D7%A2%D7%AA%20%D7%94%D7%A8%D7%91%D7%A2%D7%95%D7%A0%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwczyyub.rjb-7czcsu8&start=20220704&end=20261112&filename=GURU_Markets_-_IDYA_-_IDEAYA-Biosciences_-_Earnings-per-share-for-the-last-four-quarters "IDEAYA Bio - רווח נקי למניה (EPS TTM) IDYA (תקופה 04.07.2022 - 12.11.2026) | 👁️GURU.Markets👁️")
פילוחים אנליטיים של חברת IDEAYA Biosciences
Analyzing the net income per share over the last 12 months allows for an assessment of the efficiency of IDEAYA Biosciences (IDYA) in developing targeted oncology drugs, accounting for diversification through partnerships. This indicator captures the rolling total of profit while excluding the impact of share volume, enabling the identification of historical extremes and neutralizing temporary distortions from one-off transactions to evaluate capital stability.
